SUMMARY A bedtime dose of sulphamethoxazole was effective in preventing ear infections in otitis-prone young children. Thirty-three such children were studied by means of a random, doubleblind, placebo-controlled, cross-over protocol. Nine (27%) of 33 children treated with sulphamethoxazole experienced 10 episodes of acute suppurative otitis media or otitis media with effusion while 19 (58 %) of 33 children given a placebo experienced 27 episodes of acute otitis media or otitis media with effusion. No new episode of otitis media was observed in 11 children in whom serial urine samples uniformly had a positive response to Micrococcus lutea bioinhibition test, the method we chose to monitor compliance. Otitis media with effusion (secretory otitis media) was detected less often in the children who were given sulphamethoxazole; this fact suggests that prophylaxis with sulphamethoxazole may prevent persistent middle ear effusion in otitis-prone young children. These children were drawn from two suburban private paediatric practices. A letter explaining the purpose of the study was sent to parents of any child who had had multiple episodes of acute otitis media. All patients had experienced at least three episodes of acute otitis media in the preceding 12-month period, and with few exceptions, had had recent attacks. Twenty-nine children had experienced a total of 62 episodes of acute otitis media in the preceding 3-month period, while 4 children had had the third episode longer than 3 months before the study. The patients were assigned at random to a set of coded bottles by a project nurse who did not know the child's history or the condition of the middle ear on entry into the study.
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A young child who has had at least three episodes of otitis media within the previous 12 months has been called 'otitis-prone'.1 Data derived from a longitudinal study conducted in a private practice in Huntsville, Alabama1 and a collaborative study from Boston Compliance with the study regimen was encouraged by asking the parents to affix a printed reminder of the protocol to the refrigerator door. In addition, mothers were asked to collect a urine specimen in a numbered vial on the day of each follow-up visit and to place the vial immediately in the freezer compartment of the home refrigerator. Urine specimens were tested for antibacterial activity using a Micrococcus lutea bioinhibition assay using the method of Charney et al.10
Results
After random assignment and during the initial period of the study, 10 children dropped out, 6 taking SMZ and 4 the placebo. Six of these 10 patients failed to return for follow-up visits during the first month and were excluded from the study. Three children refused to take the bitter tasting SMZ and were also excluded.
A total of 9 (27 %) of the 33 SMZ-treated children experienced 10 episodes of acute otitis media or otitis media with effusion in contrast to 19 (57.5%) of the 33 children in the placebo group who experienced 27 episodes of acute otitis media or otitis media with effusion. The difference between the number of children with acute otitis and otitis media with effusion in each treatment group is significant (x* = 2.25 P<0-02). Four placebotreated children had two episodes of acute otitis media or acute otitis media with effusion and 2 placebo-treated patients had three episodes. One SMZ-treated child had two episodes of acute otitis media or acute otitis media with effusion and none had three episodes.
During the initial 2 months of the study, four episodes of acute suppurative otitis media or acute otitis media with effusion were noted in 17 children who received SMZ prophylactically. In contrast, 12 episodes of acute otitis media or acute otitis media with effusion were detected in 16 children who received the placebo (x* = 2-87 P<0.01). After cross-over, 2 months later, five episodes of otitis media were noted in the 17 children who received the placebo (Table 1) .
No significant difference was noted between the two treatment groups during the second 2-month interval in this study. However, there is a significant decrease from twelve episodes of otitis media in the 16 children who received the placebo during phase one, to five episodes after cross-over to SMZ (x* = 2-5 P<0.02). By comparison, those who received SMZ in phase one suffered only four episodes of otitis media. After cross-over to placebo, they had seven episodes of otitis media. This difference is not significant. However, during the entire 4-month period, the number of episodes of otitis media in patients who started the study on placebo (twelve episodes in 16 patients) does differ significantly from the number of episodes of otitis media observed in the group who started the study on SMZ prophylaxis (7 episodes in 17 patients) x* -1 -98 P<0*05. Regardless of the type of treatment, 11 (33 %) of 33 children in the study had no episode of otitis media during the 4-month study period; however, 3 of these 11 otitis-free children developed otitis media during an 8-week observation period immediately after the study ended. Our study modelled closely to that of Perrin and associates, leads us to conclude, as they did, that sulphonamide chemoprophylaxis is effective in reducing episodes of acute otitis media in otitisprone young children; however, some differences are apparent in the designs of these two studies.
Because Perrin et al. found no benefits to chemoprophylaxis in 18 children older than 5 years of age, we limited our study to children of 72 months or younger. Instead of using a twice daily dose of sulphafurazole, we chose a single bedtime dose. Moreover, in our study, compliance was monitored by testing serial urine specimens for bioinhibitory activity, while Perrin et al. ascertained the volume of sulphonamide suspension periodically. In Perrin's study, neither tympanometry nor pneumo-otoscopy was used to diagnose otitis media with effusion. Since publication of the earlier study, the importance of otitis media with effusion and its diagnosis by pneumo-otoscopy or tympanometry has been appreciated.
We found that signs and symptoms of otitis media were more likely to occur in children with otitis media with effusion who changed to the placebo during the second 2-month period. It is tempting to speculate that the more rapid resolution of otitis media with effusion in children receiving the study drug made them less likely to have acute otitis media. Perhaps sulphonamide reduces the frequency and duration of otitis media with effusion as well as preventing episodes of acute otitis media.
We think that chemoprophylaxis for recurrent otitis media may act in a similar manner to lowdose sulphonamides in preventing recurrent urinary tract infection. Sulphonamides are generally active against two common bacteria causing otitis media and are attractive chemoprophylactic agents because they have a low incidence of side effects. 
